Zacks.com on MSN1d
Catalent Stock Flat Following the Sell Agreement With ArdenaCatalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and ...
On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.65 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.45. The stock opened at $60.5 and ...
Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have received an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight ...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...
On Thursday, Catalent Inc (CTLT) stock saw a decline, ending the day at $60.71 which represents a decrease of $-0.25 or -0.41% from the prior close of $60.96. The stock opened at $60.78 and touched a ...
Investors might want to bet on Catalent (CTLT), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...
Catalent, Inc. (NYSE: CTLT) announced that it has completed the expansion of its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent's flagship European facility ...
Financial groups and labor unions urge FTC to block Nordisk Foundation's acquisition of Catalent, citing concerns about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback